South Korea Retains Neuronata-R Stem Cell Therapy Approval

South Korea Upholds Neuronata-R ALS Stem Cell Therapy Approval; CorestemChemon Eyes U.S. BLA Filing 

SEOUL, South Korea — July 20, 2026 — South Korea's Ministry of Food and Drug Safety (MFDS) has confirmed the continued market authorization of Neuronata-R® (lenzumestrocel), an autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS), following a product license modification approved in May 2026. The decision preserves patient access to one of the few cell-based treatment options available for ALS in the country and signals a broader push by developer CorestemChemon to expand the therapy's reach into the United States. 

Main Development 

The MFDS approved a label update for Neuronata-R® to incorporate data from the completed ALSUMMIT (NCT04745299) Phase 3 clinical trial, which the regulator accepted as the basis for maintaining the therapy's conditional approval — first granted in 2014. While the trial did not achieve statistical significance across the full study population, the slow-progressor subgroup met the primary endpoint, the Combined Assessment of Function and Survival (CAFS), as well as a secondary endpoint on the ALS Functional Rating Scale-Revised (ALSFRS-R), alongside consistent improvement in slow vital capacity (SVC). 

The same subgroup demonstrated a reduction in neurofilament light chain (NfL), a biomarker of axonal damage that is gaining increasing acceptance in ALS regulatory decision-making. To date, more than 400 patients in South Korea have received the therapy, generating a substantial body of real-world safety data. 

CorestemChemon is now working to resume full-scale manufacturing, which is expected to be operational in early 2027, at which point patients from outside South Korea will also be able to travel to the country to receive the treatment. On the regulatory front, the company confirmed it is pursuing a Type C meeting with the U.S. Food and Drug Administration (FDA), with the goal of filing a Biologics License Application (BLA) for U.S. approval next year. 

In a parallel strategic move, CorestemChemon became the first South Korean company to join the Piedmont Triad Regenerative Medicine Engine — an innovation platform supported by the U.S. National Science Foundation (NSF) and anchored by the Wake Forest Institute for Regenerative Medicine (WFIRM) — in late 2025. The company has consolidated its U.S. operations in North Carolina to anchor that research footprint. 

Neuronata-R® holds Orphan Drug Designation from both the FDA, granted in 2018, and the European Medicines Agency (EMA), granted in 2019. 

Key Highlights: 

• South Korea's MFDS approved a product license modification for Neuronata-R® in May 2026, maintaining its conditional approval first granted in 2014 and preserving access for ALS patients. 

• In the ALSUMMIT Phase 3 trial, the therapy met its primary endpoint (CAFS) and a secondary endpoint (ALSFRS-R) in the slow-progressor subgroup, alongside a reduction in the NfL biomarker of axonal damage. 

• CorestemChemon is pursuing a Type C meeting with the U.S. FDA, targeting a Biologics License Application (BLA) filing for U.S. approval in 2027, with full-scale manufacturing resumption expected in early 2027. 

• The company became the first South Korean firm to join the NSF-supported Piedmont Triad Regenerative Medicine Engine, anchored by Wake Forest Institute for Regenerative Medicine, consolidating its U.S. research base in North Carolina. 

Analyst Insight: 

According to analysts at Next Move Strategy Consulting, the Regenerative Medicine Market is projected to reach USD 95.48 billion by 2030, expanding at a CAGR of 17.9% from 2024 to 2030. NMSC analysts note that regulatory milestones such as the MFDS label update for Neuronata-R® reflect a broader global trend toward evidence-based conditional approvals for cell and gene therapies targeting rare and terminal diseases. The growing acceptance of biomarkers such as NfL as a basis for regulatory decisions is expected to accelerate the development pipeline for stem cell-based neurological therapies, particularly in markets where unmet clinical need remains high. 

Industry Outlook: 

The Neuronata-R® regulatory update in South Korea, combined with CorestemChemon's active pursuit of U.S. FDA engagement, underscores the increasing cross-border momentum within the regenerative medicine sector. As Asia-Pacific continues to emerge as a significant contributor to global cell therapy development — supported by rising clinical trial activity and strategic partnerships with U.S. research institutions — the pathway from conditional approval to full market authorization in major regulatory jurisdictions is becoming more clearly defined. The anticipated BLA filing and manufacturing scale-up in 2027 will be closely monitored by industry stakeholders as a potential indicator of how Asian-origin stem cell therapies navigate the U.S. regulatory landscape. 

Source: The Manila Times 

For More Information – Download FREE Sample on Regenerative Medicine Market Report

Prepared By: Sanyukta Deb